GlassScriptPhysician profile
Ruchi D Bhatt
NPI 1265773865
$3,698.68
in general payments reported to CMS, 2019-2025
41 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $12.04 · 2021: $46.77 · 2022: $433 · 2023: $593 · 2024: $810 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.59 |
| Education | $197.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $336.21 | 2022-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $326.95 | 2020-2025 | Opdivo, Opdualag, Eliquis |
| Abbvie INC. | $246.49 | 2019-2025 | Venclexta |
| Daiichi Sankyo INC. | $246.30 | 2024-2025 | Enhertu |
| Amgen INC. | $226.26 | 2019-2023 | Kyprolis |
| Novocure INC. | $219.82 | 2025 | Optune Lua (Novottf-200t) |
| Mirati Therapeutics, INC. | $199.83 | 2023-2024 | Krazati |
| Celgene Corporation | $187.57 | 2019-2023 | Pomalyst |
| Eisai INC. | $183.07 | 2022-2025 | |
| Glaxosmithkline, LLC. | $171.36 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Novartis Pharmaceuticals Corporation | $148.13 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.83 | 2019 | |
| Taiho Oncology, INC. | $108.90 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $89.88 | 2024-2025 | Enhertu, Tagrisso |
| Ge Healthcare | $79.97 | 2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $74.77 | 2024-2025 | Orserdu |
| Merck Sharp & Dohme LLC | $60.62 | 2022-2023 | Keytruda |
| Springworks Therapeutics, INC. | $56.60 | 2024-2025 | Ogsiveo |
| Janssen Biotech, INC. | $49.08 | 2021-2024 | Tecvayli |
| Aveo Pharmaceuticals, INC. | $45.18 | 2022 | |
| Lilly USA, LLC | $44.10 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $43.62 | 2022-2025 | Monjuvi, Pemazyre, Jakafi |
| Pharmacosmos Therapeutics INC. | $38.03 | 2024 | Monoferric, Cosela |
| Servier Pharmaceuticals LLC | $33.73 | 2023-2024 | |
| Puma Biotechnology, INC. | $33.67 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $32.67 | 2023-2024 | Empaveli |
| Astellas Pharma US INC | $31.02 | 2022 | |
| Seagen INC. | $28.41 | 2023 | Padcev, Adcetris |
| Beone Medicines USA, INC. | $22.14 | 2025 | Brukinsa |
| Genentech USA, INC. | $21.55 | 2023 | Tecentriq, Alecensa, Gavreto |
| Genmab U.S., INC. | $21.07 | 2025 | Tivdak |
| Exact Sciences Corporation | $19.62 | 2025 | Cologuard Collection Kit |
| Rigel Pharmaceuticals, INC. | $18.03 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Acrotech Biopharma INC. | $17.70 | 2023 | Beleodaq |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $16.44 | 2023 | Imbruvica, Epkinly |
| Cumberland Pharmaceuticals, INC. | $16.44 | 2023 | Sancuso |
| Beigene USA, INC. | $16.25 | 2023 | Brukinsa |
| Emd Serono, INC. | $16.21 | 2024 | |
| Iovance Biotherapeutics, INC. | $14.80 | 2025 | Amtagvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.34 | 2023 | Gilotrif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchi Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.